At Zalgen Labs, we are dedicated to making a meaningful difference in developing and deploying medical countermeasures against neglected tropical diseases.


Andersen KG, Shapiro BJ, Matranga CB, (2015) Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus. Cell. 2015 Aug 13;162(4):738-50. doi: 10.1016/j.cell.2015.07.020. PubMed PMID: 26276630; PubMed Central PMCID: PMC4537774.

Boisen ML, Hartnett JN, Shaffer JG, (2018) Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. Sci Rep. 2018 Apr 12;8(1):5939. doi: 10.1038/s41598-018-24246-w. PubMed PMID: 29651117; PubMed Central PMCID: PMC5897328.

Boisen ML, Uyigue E, Aiyepada J, (2020) Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak, Sci Rep. 2020; 10: 8724. Published online 2020 May 26. doi: 10.1038/s41598-020-65736-0 PMCID: PMC7250850 ArticlePubReaderPDF–1.5MCitation Select item 6438490

Branco LM, Matschiner A, Fair JN, (2008) Bacterial-based systems for expression and purification of recombinant Lassa virus proteins of immunological relevance. Virol J. 2008 Jun 6;5:74. doi: 10.1186/1743-422X-5-74. PubMed PMID: 18538016; PubMed Central PMCID: PMC2435526.

Branco LM, Garry RF (2009) Characterization of the Lassa virus GP1 ectodomain shedding: implications for improved diagnostic platforms. Virol J. 2009 Sep 24;6:147. doi: 10.1186/1743-422X-6-147. PubMed PMID: 19778448; PubMed Central PMCID: PMC2759938.

Branco LM, Grove JN, Geske FJ, (2010) Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.  Virol J. 2010 Oct 20;7:279. doi: 10.1186/1743-422X-7-279. PubMed PMID: 20961433; PubMed Central PMCID: PMC2984592.

Branco LM, Grove JN, Moses LM, (2010) Shedding of soluble glycoprotein 1 detected during acute Lassa virus infection in human subjects. Virol J. 2010 Nov 9;7:306. doi: 10.1186/1743-422X-7-306. PubMed PMID: 21062490; PubMed Central PMCID: PMC2993672.

Branco LM, Boisen ML, Andersen KG, (2011) Lassa hemorrhagic fever in a late term pregnancy from northern Sierra Leone with a positive maternal outcome: case report. Virol J. 2011 Aug 15;8:404. doi: 10.1186/1743-422X-8-404. PubMed PMID: 21843352; PubMed Central PMCID: PMC3177908.

Branco LM, Grove JN, Boisen ML, (2011) Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. Virol J. 2011 Oct 24;8:478. doi: 10.1186/1743-422X-8-478. PubMed PMID: 22023795; PubMed Central PMCID: PMC3223505.

Cross RW, Mire CE, Branco LM, (2016) Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. Antiviral Res. 2016 Sep;133:218-222. doi: 10.1016/j.antiviral.2016.08.012. Epub 2016 Aug 13. PubMed PMID: 27531367; PubMed Central PMCID: PMC5032844.

Grove JN, Branco LM, Boisen ML, (2011) Capacity building permitting comprehensive monitoring of a severe case of Lassa hemorrhagic fever in Sierra Leone with a positive outcome: case report. Virol J. 2011 Jun 20;8:314. doi: 10.1186/1743-422X-8-314. PubMed PMID: 21689444; PubMed Central PMCID: PMC3283910.

Hastie KM, Zandonatti MA, Kleinfelter LM, (2017) Structural basis for antibody-mediated neutralization of Lassa virus. Science. 2017 Jun 2;356(6341):923-928. doi: 10.1126/science.aam7260. PubMed PMID: 28572385; PubMed Central PMCID: PMC6007842.

Heinrich ML, Boisen ML, Nelson DKS, (2020) Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross‑react with recombinant proteins representing Lassa viruses of divergent lineages. Scientific Reports 10:16030 |

Illick MM, Branco LM, Fair JN, (2008) Uncoupling GP1 and GP2 expression in the Lassa virus glycoprotein complex: implications for GP1 ectodomain shedding. Virol J. 2008 Dec 23;5:161. doi: 10.1186/1743-422X-5-161. PubMed PMID: 19105844; PubMed Central PMCID: PMC2645378.

Mire CE, Cross RW, Geisbert JB, (2017) Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat Med. 2017 Oct;23(10):1146-1149. doi: 10.1038/nm.4396. Epub 2017 Sep 4. PubMed PMID: 28869611; PubMed Central PMCID: PMC5719877.

Robinson JE, Hastie KM, Cross RW, (2016) Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat Commun. 2016 May 10;7:11544. doi: 10.1038/ncomms11544. PubMed PMID: 27161536; PubMed Central PMCID: PMC4866400.

Safronetz D, Sogoba N, Diawara SI, (2017) Annual Incidence of Lassa Virus Infection in Southern Mali. Am J Trop Med Hyg. 2017 Apr;96(4):944-946. doi: 10.4269/ajtmh.16-0821. Epub 2017 Jan 16. PubMed PMID: 28093544; PubMed Central PMCID: PMC5392646.

Shaffer JG, Grant DS, Schieffelin JS, (2021) Space-Time Trends in Lassa Fever in Sierra Leone by ELISA Serostatus, 2012–2019. Microorganisms. 2021 Mar 12;9(3):586. doi: 10.3390/microorganisms9030586. PMCID: PMC8000031.

Shaffer JG, Grant DS, Schieffelin JS, (2014) Lassa fever in post-conflict Sierra Leone. PLoS Negl Trop Dis. 2014 Mar;8(3):e2748. doi: 10.1371/journal.pntd.0002748. eCollection 2014 Mar. PubMed PMID: 24651047; PubMed Central PMCID: PMC3961205.

Shaffer JG, Schieffelin JS, Gbakie M, (2019) A medical records and data capture and management system for Lassa fever in Sierra Leone: Approach, implementation, and challenges, PLoS One. 2019; 14(3): e0214284. Published online 2019 Mar 28. doi: 10.1371/journal.pone.0214284, PMCID: PMC6438490

Sogoba N, Rosemke K, Adjemian J, (2016) Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali. Emerg Infect Dis. 2016 Apr;22(4):657-63. doi: 10.3201/eid2204.151814. PubMed PMID: 26981786; PubMed Central PMCID: PMC4806955.[/vc_column_text][vc_separator css=".vc_custom_1578687451430{padding-top: 10px !important;padding-bottom: 10px !important;}"][vc_column_text]


Boisen ML, Oottamasathien D, Jones AB, (2015) Development of Prototype Filovirus Recombinant Antigen Immunoassays. J Infect Dis. 2015 Oct 1;212 Suppl 2:S359-67. doi: 10.1093/infdis/jiv353. Epub 2015 Jul 30. PubMed PMID: 26232440; PubMed Central PMCID: PMC4564556.

Boisen ML, Schieffelin JS, Goba A, (2015) Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreak. Viral Immunol. 2015 Feb;28(1):19-31. doi: 10.1089/vim.2014.0108. PubMed PMID: 25531344; PubMed Central PMCID: PMC4287116.

Boisen ML, Cross RW, Hartnett JN, (2016) Field Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection. J Infect Dis. 2016 Oct 15;214(suppl 3):S203-S209. doi: 10.1093/infdis/jiw261. Epub 2016 Aug 11. PubMed PMID: 27521365; PubMed Central PMCID: PMC5050478.

Boisen ML. Hartnett JN, Goba A, (2016) Epidemiology and Management of the 2013-16 West African Ebola Outbreak. Annu Rev Virol. 2016 Sep 29;3(1):147-171. doi: 10.1146/annurev-virology-110615-040056. Epub 2016 Aug 15. Review. PubMed PMID: 27578439.

Cross RW, Boisen ML, Millett MM, (2016) Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection. J Infect Dis. 2016 Oct 15;214(suppl 3):S210-S217. doi: 10.1093/infdis/jiw293. Epub 2016 Aug 31. PubMed PMID: 27587634; PubMed Central PMCID: PMC5050482.

Cross RW, Geisbert TW (2019) Use of reverse genetics to inform Ebola outbreak responses. Lancet Infect Dis. 2019 Sep;19(9):925-927. doi: 10.1016/S1473-3099(19)30346-9. Epub 2019 Jul 9. PubMed PMID: 31300333.

Goba A, Khan SH. Fonnie M,  (2016) An Outbreak of Ebola Virus Disease in the Lassa Fever Zone. J Infect Dis. 2016 Oct 15;214(suppl 3):S110-S121. doi: 10.1093/infdis/jiw239. Epub 2016 Jul 11. PubMed PMID: 27402779; PubMed Central PMCID: PMC5050470.

Schieffelin JS, Shaffer JG, Goba A, (2014) Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med. 2014 Nov 27;371(22):2092-100. doi: 10.1056/NEJMoa1411680. Epub 2014 Oct 29. PubMed PMID: 25353969; PubMed Central PMCID: PMC4318555.[/vc_column_text][vc_separator css=".vc_custom_1578687451430{padding-top: 10px !important;padding-bottom: 10px !important;}"][vc_column_text]

Sars CoV-2

Drouin AC, Theberge MW, Liu SY, (2021) Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail. Viruses. 2021, 13, 1202.

News & Events


Shopping Cart
Scroll to Top